Nonetheless, the above studies suggest increased PD-1 expression on T-cells and NK cells as well as PD-L1 on glioma cells driven by HCMV infection could negatively impact anti-PD-L1 based therapies such as durvalumab. This evidence concerns the gene CD274 and cytomegalovirus infection.